Assessment of the chemerin, IL-6, and IL-23 correlations and their impact on CRC progression: An observational study
Abstract
Introduction: The role of proinflammatory cytokines is said to be crucial in the development of colorectal cancer (CRC). IL-6, IL-23, and chemerin have all been proven to take part in tumor growth and progression. Aim of the study: to determine the level of chemerin and the concentrations of interleukin-6 (IL-6) and interleukin- 23 (IL-23) in the tumor and margin specimens of CRC in relation to histological grade and TNM staging. Material and methods: The study involved 49 samples of tumor and margin tissues obtained from CRC patients. To assess the concentration of chemerin, IL-6, and IL-23, commercially available enzyme-linked immunosorbent assay (ELISA) kits were used. Results: There was no difference in chemerin concentration between the tumor and margin. We found significantly increased levels of IL-6 in tumor tissue compared to margin tissue and higher concentrations of IL-23 in margin tissue than in tumor tissue. Tumor levels of chemerin were significantly correlated with those of IL-23, while its margin concentrations were associated with margin concentrations of IL-6. Additionally, tumor levels of IL-23 were positively correlated with margin levels of IL-6. Conclusions: Chemerin might play an important role in CRC progression through its association with cytokine expression. More studies are needed to investigate the possible role of IL-6, IL-23, and chemerin as potential markers in the development of CRC.
Keywords: ChemerinInterleukin-6 (IL-6)Interleukin-23 (IL-23)Colorectal Cancer (CRC)
References
- Zeng J, Tang ZH, Liu S, et al. Clinicopathological significance of overexpression of interleukin-6 in colorectal cancer. World J Gastroenterol. 2017; 23(10): 1780–1786.
- World Cancer Research Fund. Worldwide cancer data. https://www.wcrf.org/cancer-trends/worldwide-cancer-data/ (9.05.2022).
- Centers for Disease Control and Prevention. An Update on Cancer Deaths in the United States.: Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, Division of Cancer Prevention and Control; 2022.
- Akimoto N, Ugai T, Zhong R, et al. Rising incidence of early-onset colorectal cancer - a call to action. Nat Rev Clin Oncol. 2021; 18(4): 230–243.
- Jasperson K, Tuohy T, Neklason D, et al. Hereditary and Familial Colon Cancer. Gastroenterology. 2010; 138(6): 2044–2058.
- Thanikachalam K, Khan G. Colorectal Cancer and Nutrition. Nutrients. 2019; 11(1).
- Roguska J, Zubkiewicz-Kucharska A. Chemerin as an early marker of metabolic syndrome. Pediatric Endocrinology Diabetes and Metabolism. 2018; 24(1): 45–51.
- Helfer G, Wu QF. Chemerin: a multifaceted adipokine involved in metabolic disorders. J Endocrinol. 2018; 238(2): R79–R94.
- Eichelmann F, Schulze MB, Wittenbecher C, et al. Association of chemerin plasma concentration with risk of colorectal cancer. JAMA Netw Open. 2019; 2(3): e190896.
- Komoda H, Tanaka Y, Honda M, et al. Interleukin-6 levels in colorectal cancer tissues. World J Surg. 1998; 22(8): 895–898.
- Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014; 2(4): 288–294.
- Waldner MJ, Foersch S, Neurath MF. Interleukin-6 - a key regulator of colorectal cancer development. Int J Biol Sci. 2012; 8(9): 1248–1253.
- Lan F, Zhang Le, Wu J, et al. IL-23/IL-23R: potential mediator of intestinal tumor progression from adenomatous polyps to colorectal carcinoma. Int J Colorectal Dis. 2011; 26(12): 1511–1518.
- Adamo V, Franchina T, Minciullo PL, et al. Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives. J Cell Physiol. 2011; 226(11): 3032–3034.
- Yan J, Smyth MJ, Teng MWL. Interleukin (IL)-12 and IL-23 and their conflicting roles in cancer. Cold Spring Harb Perspect Biol. 2018; 10(7).
- Alkady MM, Abdel-Messeih PL, Nosseir NM. Assessment of serum levels of the adipocytokine chemerin in colorectal cancer patients. J Med Biochem. 2018; 37(3): 313–319.
- Chonov DC, Ignatova MM, Ananiev JR, et al. IL-6 activities in the tumour microenvironment. Part 1. Open Access Maced J Med Sci. 2019; 7(14): 2391–2398.
- Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer. 1999; 85(12): 2526–2531, doi: 10.1002/(sici)1097-0142(19990615)85:12<2526::aid-cncr6>3.0.co;2-3.
- Lo CH, Lee SC, Wu PY, et al. Antitumor and antimetastatic activity of IL-23. J Immunol. 2003; 171(2): 600–607.
- Suzuki H, Ogawa H, Miura K, et al. IL-23 directly enhances the proliferative and invasive activities of colorectal carcinoma. Oncol Lett. 2012; 4(2): 199–204.
- Ljujic B, Radosavljevic G, Jovanovic I, et al. Elevated serum level of IL-23 correlates with expression of VEGF in human colorectal carcinoma. Arch Med Res. 2010; 41(3): 182–189.
- FM R, S H, MA Z, et al. Evaluation of expression pattern of vascular endothelial growth factor (VEGF) and interleukin-23 (IL-23) genes in human colorectal tumors. Journal of Molecular and Genetic Medicine. 2018; 12(1).
- Wang J, Xu K, Wu J, et al. The changes of Th17 cells and the related cytokines in the progression of human colorectal cancers. BMC Cancer. 2012; 12: 418.
- Kim DK, Oh SY, Kwon HC, et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 2009; 9: 155.
- Chung YC, Chaen YL, Hsu CP. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. Anticancer Res. 2006; 26(5B): 3905–3911.
- Shiga K, Hara M, Nagasaki T, et al. Preoperative serum interleukin-6 is a potential prognostic factor for colorectal cancer, including stage II patients. Gastroenterol Res Pract. 2016; 2016: 9701574.
- Stanilov N, Miteva L, Deliysky T, et al. Advanced colorectal cancer is associated with enhanced IL-23 and IL-10 serum levels. Laboratory Medicine. 2010; 41(3): 159–163.
- Zhang Le, Li J, Li Li, et al. IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway. Carcinogenesis. 2014; 35(6): 1330–1340.
- Wang K, Karin M. The IL-23 to IL-17 cascade inflammation-related cancers. Clin Exp Rheumatol. 2015; 33(Suppl 92): S87–90.
- Elessawi DF, Alkady MM, Ibrahim IM. Diagnostic and prognostic value of serum IL-23 in colorectal cancer. Arab J Gastroenterol. 2019; 20(2): 65–68.